Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(67%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (33.3%)
N/A2 (66.7%)

Trials by Status

completed133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

Adipose Tissue Imaging in Type 2 Diabetes

NCT02528695
terminatedphase_4

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

NCT01409993
terminatednot_applicable

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

NCT02282423

Clinical Trials (3)

Showing 3 of 3 trials
NCT02528695Not Applicable

Adipose Tissue Imaging in Type 2 Diabetes

Completed
NCT01409993Phase 4

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

Terminated
NCT02282423Not Applicable

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3